Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No one does it butter!
Omg! Seriously you all. You have invested in a pre-revenue biotech listed on otc. We don't have no institutional support yet. If you don't like the communication move on! This is the program until we get a partnership and uplist.
Lmao! Way to much wailing and gnashing of teeth today. B-OM could easily be a billion dollar drug soon enough!
Why are you still focusing on the mild psoriasis patients in the 200 mg arm since neither mild psoriasis nor 200 mg are involved in Phase 2b?
Great question great piont!
Our management team has done a great job of analysing early trial data and tweeking the next trial. At this point you either have faith that they know what they are doing or you don't.
Sox our management team has done a great job of analysing early trial data and tweeking the next trial. I think they have earned the right to keep the P trial moving forward. Thanks for all you do hear!
If you are a b fan then you might remember that B 2a had some questionable results and serious safety concerns. But our management team saw enough to go back to the labs and come up with the right changes for a successful B2b. So in my eyes they have earned the right to have a P2b.
My question still stands why are you invested here if you don't believe in the drugs?
But that's what makes mild psoriasis so challenging and difficult to create a trial around but it is a huge market opportunity.
Those who wish the companies pps to go/stay down know that they have time on their side because there is only so much news and the timing is pretty well known...until it's not.
That is the nature of mild psoriasis. It waxes and wanes more than more severe psoriasis. Biodoc and others have gone over this many times.
Looks like we closed the opening gap.
You understand that in these documents they have to say these things! Seriously! Lmao
You mean 10q? And why the delay?
Well said. Thanks
It's fine with me.
Again we get it you don't like P. Time will tell.
Ask yourself is the company progressing the science? Because at the end of the day that's all BP care about!
So your investing strategy is wrong/bad that's not managements fault! Get out now! Save yourself any more headaches!
I just want to hear from 1! Come on Max. Why? Please tell me what are you hear for? You spend hours hating management. Why?
I would love to hear from just one "investor" who disagrees with managements trial decisions yet continues to remain an "investor".
They changed the P2B study by increasing the dose, changing the population (mild-moderate v moderate to severe) and the scale. I get your point on 2a ...small numbers etc. But if you don't trust management why are you investing? Care to share?
Biotech investing. Delays changes surprises. People on this board railed against this same management team for spending money on B.
Ok! Got it! Your not a P fan! We will all know one way or the other soon enough.
I understand your concern but I think the anti-inflammatory properties are what really help
Good. As nice as it would be to have 1 deal for B I just can't imagine 1 BP having the $'s, expertise or infrastructure to exploit all of B.
Do you think we will see separate deals by indications for B?
Thanks for the report DaubersUP! Nice work
When you find the perfect CEO please let us know! LMAO! Leo has done a fine job managing the science with a pre-revenue biotech budget.
The science has progressed nicely since 2015. B-UP B-OM P2(a,b) K P2.
I have been very impressed with the progress and speed of progress of late. I was convinced then and I am even more convinced now that Leo cares about his shareholders This is what you said in your very first post on the board What's changed? More trial progression that's all
Lmao! Why in the hell would you bring up our advantages as a disadvantage? Seriously!
Obviously you didn't follow it closely enough or you wouldn't have commented on "bugs learning".
You really should do dd before you make comments like that.
One of the reasons imo that the company hasn't proceed with the phase 3 trial for abbssi is because the anti-inflammatory properties are worth much more. So they have elected to run and complete 2 additional trials which have proven the anti-inflammatory properties and now the entire B franchise is exponentially more valuable.
The point is we will see topline results no later than 1st quarter 2018.
December was the anticipated date! He was reaffirming that they were still on track and you have know idea what the results will be.
Since there are no good treatments for this debilitating condition, I would say there is a great chance for breakthrough designation.
Brilacidin the gift that keeps on giving!
awesome news! B-OM topline results due anytime! Breakthrough designation and partnership soon after!